K
Kenneth Koury
Researcher at Pfizer
Publications - 44
Citations - 24900
Kenneth Koury is an academic researcher from Pfizer. The author has contributed to research in topics: Ribavirin & Medicine. The author has an hindex of 22, co-authored 35 publications receiving 15959 citations. Previous affiliations of Kenneth Koury include Schering-Plough & Merck & Co..
Papers
More filters
Journal ArticleDOI
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
Fernando P. Polack,Stephen J. Thomas,Nicholas Kitchin,Judith Absalon,Alejandra Gurtman,Stephen Lockhart,John L. Perez,Gonzalo Pérez Marc,Edson D. Moreira,Cristiano Zerbini,Ruth Bailey,Kena A. Swanson,Satrajit Roychoudhury,Kenneth Koury,Ping Li,Warren Kalina,David A. Cooper,Robert W. Frenck,Laura L. Hammitt,Özlem Türeci,Haylene Nell,Axel Schaefer,Serhat Ünal,Dina B. Tresnan,Susan Mather,Philip R. Dormitzer,Ugur Sahin,Kathrin U. Jansen,William C. Gruber +28 more
TL;DR: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older and safety over a median of 2 months was similar to that of other viral vaccines.
Journal ArticleDOI
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.
Michael P. Manns,John G. McHutchison,Stuart C. Gordon,Vinod K. Rustgi,Mitchell L. Shiffman,Robert Reindollar,Zachary Goodman,Kenneth Koury,Mei Hsiu Ling,Janice K. Albrecht +9 more
TL;DR: In patients with chronic hepatitis C, the most effective therapy is the combination of peginterferon alfa-2b 1.5 microg/kg per week plus ribavirin, and this randomised trial found that the benefit is mostly achieved in patients with HCV genotype 1 infections.
Journal ArticleDOI
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates.
Edward E. Walsh,Robert W. Frenck,Ann R. Falsey,Ann R. Falsey,Nicholas Kitchin,Judith Absalon,Alejandra Gurtman,Stephen Lockhart,Kathleen M. Neuzil,Mark J. Mulligan,Ruth Bailey,Kena A. Swanson,Ping Li,Kenneth Koury,Warren Kalina,David A. Cooper,Camila R. Fontes-Garfias,Pei Yong Shi,Özlem Türeci,Tompkins Kristin Rachael,Kirsten E. Lyke,Vanessa Raabe,Philip R. Dormitzer,Kathrin U. Jansen,Ugur Sahin,William C. Gruber +25 more
TL;DR: The safety and immunogenicity data from this U.S. phase 1 trial of two vaccine candidates in younger and older adults support the selection of BNT162b2 for advancement to a pivotal phase 2–3 safety and efficacy evaluation.
Journal ArticleDOI
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.
John G. McHutchison,Eric Lawitz,Mitchell L. Shiffman,Andrew J. Muir,Greg Galler,Jonathan McCone,L. Nyberg,William M. Lee,Reem Ghalib,Eugene R. Schiff,Joseph S. Galati,Bruce R. Bacon,M. Davis,Pabak Mukhopadhyay,Kenneth Koury,Stephanie Noviello,Lisa D. Pedicone,Clifford A. Brass,Janice K. Albrecht,Mark S. Sulkowski +19 more
TL;DR: In patients infected with HCV genotype 1, the rates of sustained virologic response and tolerability did not differ significantly between theTwo available peginterferon-ribavirin regimens or between the two doses of pegin terferon alfa-2b.
Journal ArticleDOI
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults.
Mark J. Mulligan,Kirsten E. Lyke,Nicholas Kitchin,Judith Absalon,Alejandra Gurtman,Stephen Lockhart,Kathleen M. Neuzil,Vanessa Raabe,Ruth Bailey,Kena A. Swanson,Ping Li,Kenneth Koury,Warren Kalina,David A. Cooper,Camila R. Fontes-Garfias,Pei Yong Shi,Özlem Türeci,Tompkins Kristin Rachael,Edward E. Walsh,Edward E. Walsh,Robert W. Frenck,Ann R. Falsey,Ann R. Falsey,Philip R. Dormitzer,William C. Gruber,Ugur Sahin,Kathrin U. Jansen +26 more
TL;DR: In a dose-escalation study of the COVID-19 RNA vaccine BNT162b1 in 45 healthy adults, RBD-binding IgG concentrations and SARS-CoV-2 neutralizing titres in sera increased with dose level and after a second vaccine dose.